CD40 and cancer: Moreover, Linde and colleagues discovered that combined therapies of CD40 agonist, tumour necrosis factor and tumour‐binding antibodies induced activation of neutrophils via C5a, which subsequently mediated oxidative damage and facilitated T cell‐independent cancer cell clearance.88